| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Y C Patel, S Ezzat, C L Chik, O P Rorstad, O Serri, E Ur, G E Wilkin. Guidelines for the diagnosis and treatment of acromegaly: a Canadian perspective. Clinical and investigative medicine. Medecine clinique et experimentale. vol 23. issue 3. 2000-11-20. PMID:10911548. |
this review provides an update on our current understanding of the pathophysiology of gh hypersecretion in acromegaly, the newly defined diagnostic criteria and the end point for a cure for acromegaly, and on new developments in drug treatment with the advent of slow-release forms of somatostatin analogues and the longer-acting dopamine receptor agonists, as well as in the area of radiotherapy. |
2000-11-20 |
2023-08-12 |
Not clear |
| A Colao, P Marzullo, S Spiezia, A Giaccio, D Ferone, G Cerbone, A Di Sarno, G Lombard. Effect of two years of growth hormone and insulin-like growth factor-I suppression on prostate diseases in acromegalic patients. The Journal of clinical endocrinology and metabolism. vol 85. issue 10. 2000-11-15. PMID:11061535. |
moreover, chronic gh and igf-i excess causes prostate overgrowth in patients with acromegaly. |
2000-11-15 |
2023-08-12 |
Not clear |
| G Barrande, M Pittino-Lungo, J Coste, D Ponvert, X Bertagna, J P Luton, J Berthera. Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. The Journal of clinical endocrinology and metabolism. vol 85. issue 10. 2000-11-15. PMID:11061538. |
conventional radiotherapy is usually indicated in acromegaly when surgery fails to normalize gh secretion. |
2000-11-15 |
2023-08-12 |
Not clear |
| G Barrande, M Pittino-Lungo, J Coste, D Ponvert, X Bertagna, J P Luton, J Berthera. Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. The Journal of clinical endocrinology and metabolism. vol 85. issue 10. 2000-11-15. PMID:11061538. |
in conclusion, conventional radiotherapy can reduce gh levels below the optimal level of 2.5 microg/l and normalize igf-i levels in acromegaly. |
2000-11-15 |
2023-08-12 |
Not clear |
| N Gervaise, H Combe, P Lecomt. [Acromegaly in 2000]. Annales d'endocrinologie. vol 61. issue 3. 2000-11-13. PMID:10970950. |
the recent development of gh analogs offers new perspectives for the treatment of acromegaly. |
2000-11-13 |
2023-08-12 |
Not clear |
| S Cannavò, S Squadrito, L Curtò, B Almoto, A Vieni, F Trimarch. Results of a two-year treatment with slow release lanreotide in acromegaly. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 32. issue 6. 2000-11-03. PMID:10898551. |
srl decreases significantly gh and igf-1 in most cases and induces the shrinkage of the pituitary tumor in some patients previously either untreated or both treated for acromegaly. |
2000-11-03 |
2023-08-12 |
Not clear |
| T Tsushima, Y Katoh, Y Miyachi, K Chihara, A Teramoto, M Irie, Y Hashimot. Serum concentrations of 20K human growth hormone in normal adults and patients with various endocrine disorders. Study Group of 20K hGH. Endocrine journal. vol 47 Suppl. 2000-10-25. PMID:10890176. |
the proportion of 20k hgh was significantly (p < 0.001) higher in patients with active acromegaly (9.2 +/- 2.2%, n=33) and in patients with anorexia nervosa (9.0 +/- 1.9, n=8), both of which are characterized by chronic elevation of circulating gh levels. |
2000-10-25 |
2023-08-12 |
human |
| Y Higuchi, N Saeki, T Iuchi, Y Uchino, I Tatsuno, D Uchida, T Tanaka, Y Noguchi, S Nakamura, T Yasuda, A Yamaura, K Sunami, Y Oka, A Uozum. Incidence of malignant tumors in patients with acromegaly. Endocrine journal. vol 47 Suppl. 2000-10-25. PMID:10890185. |
this preliminary study has suggested that male patients with acromegaly might have a high risk of malignancy and that careful screening for tumors is needed both before and after surgical and medical treatment, even in patients with normalized serum gh and igf-1 levels. |
2000-10-25 |
2023-08-12 |
Not clear |
| A Colao, P Marzullo, D Ferone, L Spinelli, A Cuocolo, D Bonaduce, M Salvatore, V Boerlin, I Lancranjan, G Lombard. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. The Journal of clinical endocrinology and metabolism. vol 85. issue 9. 2000-10-16. PMID:10999798. |
the aim of the present study was to investigate the early effect of oct-lar treatment on the left ventricular (lv) structure and performance in 15 somatostatin analog-naive patients with acromegaly (gh, 94.8 +/- 24.9 mu/l; igf-i, 757.9 +/- 66.6 microg/l), focusing on the early effect of gh and igf-i suppression on the heart. |
2000-10-16 |
2023-08-12 |
Not clear |
| C A Lissett, S M Shale. Management of pituitary tumours: strategy for investigation and follow-up. Hormone research. vol 53 Suppl 3. 2000-10-11. PMID:10971108. |
the standard investigations for acromegaly consist of establishing the degree of growth hormone (gh) suppression following a glucose load and estimating the basal insulin-like growth factor-i level. |
2000-10-11 |
2023-08-12 |
Not clear |
| E R Laws, M L Vance, K Thapa. Pituitary surgery for the management of acromegaly. Hormone research. vol 53 Suppl 3. 2000-10-11. PMID:10971109. |
active acromegaly is almost always the result of a benign growth hormone (gh)-secreting adenoma of the pituitary gland. |
2000-10-11 |
2023-08-12 |
Not clear |
| E R Laws, M L Vance, K Thapa. Pituitary surgery for the management of acromegaly. Hormone research. vol 53 Suppl 3. 2000-10-11. PMID:10971109. |
the advantages of surgical excision of pituitary adenomas associated with acromegaly include: (1) prompt decrease in gh; (2) reliable and immediate relief of the mass effect from the tumor (decompression of the optic nerves and chiasm), and (3) the opportunity to obtain tumor tissue for characterization and investigative study. |
2000-10-11 |
2023-08-12 |
Not clear |
| A Colao, A Di Sarno, P Marzullo, C Di Somma, G Cerbone, M L Landi, A Faggiano, B Merola, G Lombard. New medical approaches in pituitary adenomas. Hormone research. vol 53 Suppl 3. 2000-10-11. PMID:10971110. |
in acromegaly, disease control (growth hormone [gh] <2.5-1.0 microg/l as a fasting or glucose-suppressed value, respectively, together with age-normalised insulin-like growth factor [igf]-i) is achievable in more than half of patients receiving treatment with lanreotide or octreotide-lar. |
2000-10-11 |
2023-08-12 |
Not clear |
| A Colao, A Di Sarno, P Marzullo, C Di Somma, G Cerbone, M L Landi, A Faggiano, B Merola, G Lombard. New medical approaches in pituitary adenomas. Hormone research. vol 53 Suppl 3. 2000-10-11. PMID:10971110. |
a synthetic gh analogue, b2036-peg, that antagonises endogenous gh binding to its receptor-binding sites and a gh-releasing hormone antagonist that blocks the effect of this releasing factor on the hypothalamus and pituitary are presently under investigation in acromegaly. |
2000-10-11 |
2023-08-12 |
Not clear |
| G Sassola. Growth hormone-releasing hormone: past and present. Hormone research. vol 53 Suppl 3. 2000-10-11. PMID:10971111. |
these hormones were isolated from their eutopic site of production (the hypothalamus) with the exception of growth hormone (gh)-releasing hormone (ghrh), which was isolated from an ectopic, tumoral site of production and found to be responsible for acromegaly. |
2000-10-11 |
2023-08-12 |
human |
| G F Maldonado Castro, H F Escobar-Morreale, H Ortega, D Gómez-Coronado, J A Balsa Barro, C Varela, M A Lasunció. Effects of normalization of GH hypersecretion on lipoprotein(a) and other lipoprotein serum levels in acromegaly. Clinical endocrinology. vol 53. issue 3. 2000-10-10. PMID:10971448. |
effects of normalization of gh hypersecretion on lipoprotein(a) and other lipoprotein serum levels in acromegaly. |
2000-10-10 |
2023-08-12 |
Not clear |
| N R Biermasz, H V Dulken, F Roelfsem. Postoperative radiotherapy in acromegaly is effective in reducing GH concentration to safe levels. Clinical endocrinology. vol 53. issue 3. 2000-10-10. PMID:10971449. |
postoperative radiotherapy in acromegaly is effective in reducing gh concentration to safe levels. |
2000-10-10 |
2023-08-12 |
Not clear |
| N R Biermasz, H V Dulken, F Roelfsem. Postoperative radiotherapy in acromegaly is effective in reducing GH concentration to safe levels. Clinical endocrinology. vol 53. issue 3. 2000-10-10. PMID:10971449. |
several studies have established that in treated acromegaly mortality is only normalized in patients achieving a serum gh concentration below 5 mu/l. |
2000-10-10 |
2023-08-12 |
Not clear |
| V S Herman-Bonert, K Zib, J A Scarlett, S Melme. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. The Journal of clinical endocrinology and metabolism. vol 85. issue 8. 2000-08-31. PMID:10946911. |
transsphenoidal surgical resection is the primary therapy for acromegaly caused by gh secreting pituitary adenomas. |
2000-08-31 |
2023-08-12 |
Not clear |
| N R Biermasz, H van Dulken, F Roelfsem. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. The Journal of clinical endocrinology and metabolism. vol 85. issue 7. 2000-08-08. PMID:10902796. |
in acromegaly, pituitary irradiation is a slow, but effective, intervention in decreasing gh concentration. |
2000-08-08 |
2023-08-12 |
Not clear |